Prismic’s Renal line of products is based on Palmitolyethanolamide, an endogenous fatty acid amide.  Prismic acquired the worldwide rights to Palmitoylethanolamide and the extensive portfolio of issued and pending US and international patents from Epitech SpA.  The patent portfolio covers Palmitoylethanolamide alone and in combination with other molecules across a broad array of medical conditions.  Prismic’s rights cover all indication areas and all regulatory categories, including Prescription Drugs, Medical Foods, and Nutritional Supplements.  

Palmitoylethanolamide is a molecule supported by substantial clinical and safety data. Palmitoylethanolamide is of particular interest because of recent data indicating that this molecule displays anti-inflammatory, anti-fibrotic, and analgesic properties that would allow it to serve as a renal-sparing anti-inflammatory (one that does not damage the kidney). There are also early data that suggest that Palmitoylethanolamide may reduce proteinuria.  

Prismic has two lead products derived from Palmitoylethanolamide in development for Chronic Kidney Disease (CKD), and a third product under consideration.  

NEFROSIL™ is a uniquely formulated Medical Food product under development, combining micronized Palmitoylethanolamide with Silymarin (Milk Thistle), in respect of which a patent has been filed.   

NEFROGESIC™ is a patent protected, micronized formulation of Palmitoylethanolamide in development as a Medical Food. 

A line extension is also under consideration combining micronized Palmitoylethanolamide with a form of Silymarin specifically developed to achieve increased bioavailability.    

Peripheral Neuropathic, Other Chronic Pain Conditions, and Ophthalmology Existing clinical experience suggests that Palmitoylethanolamide also has significant potential in addressing peripheral neuropathy and chronic pain, arthritic syndromes and nerve entrapment syndromes. Other data suggest promise for the treatment of elevated intraocular pressure (IOP), diabetic retinopathy, and macular degeneration. These are non-core opportunities, and, therefore, Prismic plans to out-license or partner Palmitoylethanolamide for these areas.

Central Nervous System (CNS) Disorders

The company’s CNS line of products is based on issued US and foreign patents acquired through Prismic’s purchase of the assets of Scarista Ltd. in 2011.  Scarista had acquired the worldwide license rights to this portfolio from Amarin Corporation in the area of CNS disorders.  

NEUREPA® is Prismic’s lead CNS product, a unique patented formulation of an Omega-3 triglyceride concentrate that is 92% EPA (Eicosapentaenoic Acid), has recently undergone a small field test, showing positive data and acceptance by Psychiatrists and patients.  NEUREPA® was formulated and developed specifically to address the Omega-3 deficiency in patients suffering from Depression, Bipolar Disorder, and Schizophrenia. Commercial opportunities also exist for NEUREPA® among Nephrologists and those physicians treating Depression associated with CKD; Obstetricians/Gynecologists who are high prescribers for Postpartum Depression and Depression associated with Menopause; and also Oncologists (Depression associated with Cancer), and Gynecology (Depression associated with Postpartum and Menopause).  

Line extensions of NEUREPA® are being formulated for other related patient populations and conditions, and to provide extended patent life based on the company’s existing IP portfolio.  


Prismic Pharmaceuticals